Navigation Links
Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy in Bone Cancer Model
Date:11/14/2011

MENLO PARK, Calif., Nov. 14, 2011 /PRNewswire/ -- Virobay, Inc., a privately held biotechnology firm with a broad portfolio of cysteine protease inhibitors for the treatment of autoimmune diseases, neuropathic pain, liver diseases and cancer, presented data showing that one of the company's spectrum-selective cathepsin inhibitors demonstrated efficacy in a mouse model of bone cancer pain.  Virobay has a series of advanced, spectrum-selective cathepsin inhibitors with structural diversity and demonstrated activity in bone cancer and related pain.  VBY-825, a prototype compound within this series, is an orally bioavailable, highly potent, reversible inhibitor of a subset of cathepsin proteases (including cathepsins S, K, L and B) that demonstrated protection from bone destruction and remodeling in this metastatic breast cancer model, as well as significant analgesic activity.  These preclinical data suggest that Virobay's spectrum-selective cathepsin inhibitors have potential therapeutic utility in the treatment of metastatic and primary bone cancer and cancer-related bone pain, with a mechanism of action that would be highly complementary to standard chemotherapy.

The data were presented in a poster, titled "Efficacy of a Spectrum-Selective Cathepsin Inhibitor in a Mouse Model of Bone Cancer," by Holsinger, et al., at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, on Sunday, November 13th.

"These preclinical data provide a compelling demonstration of the therapeutic potential of Virobay's cathepsin inhibitors in bone cancer and bone cancer pain," said Robert Booth, PhD, Virobay's president and chief executive officer.  "The data demonstrate that the anti-tumorigenic and analgesic activity is due to the selective targeting of specific cathepsins that are known to facilitate osteolytic metastasis, bone invasion and bone matrix degradation.  We believe that these dat
'/>"/>

SOURCE Virobay, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
2. Study Shows C1-Esterase Inhibitor Concentrate is Safe and Consistently Effective for Long-Term Treatment of Hereditary Angioedema Attacks at Any Body Location
3. Karyopharm Therapeutics Closes $10 Million Series A2 Financing to Expand Planned Phase 1 Program of Oral Selective Inhibitors of Nuclear Export (SINE) for Cancer
4. ViiV Healthcare Starts Phase III Clinical Programme of Celsentri/Selzentry® (maraviroc) versus Truvada® (tenofovir + FTC), in combination with a Protease Inhibitor in people living with HIV
5. Enantas Lead NS5A Inhibitor Candidate for HCV, EDP-239, Selected as One of Windhovers Top 10 Infectious Disease Projects to Watch
6. Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T
7. Modulation of inhibitory output is key function of antiobesity hormone
8. Neurocrine Biosciences Announces Notice of Allowance for Composition of Matter Patent on VMAT2 Inhibitor
9. Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis
10. Ardea Biosciences Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at 2011 American Society of Clinical Oncology Annual Meeting
11. Pharmacyclics Achieves $7 Million Development Milestone for HDAC Inhibitor, PCI-24781 / S 78454 with Servier
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... , ... July 03, 2015 ... ... providing industry-leading products for use in applications such as animal waste reduction, ... treatment plants and restaurant kitchen settings, announced today that it will be ...
(Date:7/3/2015)... July 3, 2015 ... verkossa osoitteessa  http://www.openinnovationinscience.at Wienissä ... in Science" -jatkokoulutusohjelmaan 22.7.2015 asti.  ... (LBG) tekemän, kansainvälisiä tutkijoita ja ... kaksi suurinta haastetta ovat kannustimien ...
(Date:7/3/2015)... Houston, Texas (PRWEB) , ... July 03, 2015 ... ... search firm, highly-regarded by Fortune 500 companies and professional service industries alike-- typically ... aimed to make clients laugh, honor a good cause and break from their ...
(Date:7/3/2015)... ... ... The global failure analysis market is expected to reach $7,147.0 million by 2020, ... to grow at the highest CAGR of 8.46%; its growth is expected to be ... academic institutions for root cause analysis of failure. The market based on the geographic ...
Breaking Biology Technology:DryLet to Highlight Benefits of Patented ManureMagic™ at North American Manure Expo in Chambersburg, PA July 14-15, 2015 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 3The Alexander Group Declares Their Independence with a Bit of Levity 2Failure Analysis Market to Grow at 7.52% CAGR to 2020 2Failure Analysis Market to Grow at 7.52% CAGR to 2020 3Failure Analysis Market to Grow at 7.52% CAGR to 2020 4Failure Analysis Market to Grow at 7.52% CAGR to 2020 5
... , , ROCKVILLE, Md., July 21 ... appointment of John J. Trizzino as Senior Vice President, International ... Trizzino will report directly to Dr. Rahul Singhvi, Novavax,s President ... managing the company,s international alliances with pharmaceutical companies and all ...
... ... is pleased the U.S. Environmental Protection Agency will allow farmers the ability to improve upon ... for SmartStax, an insect-protection and weed control platform in corn, to 5 percent in the ... ...
... , , NEWARK, N.J., July 21 ... a specialty chemical technology based Life Science Company announced ... protocol testing, BioNeutral,s Ygiene(TM) Hospital Grade Antimicrobial passed the ... all 5.4 million spores of Clostridium difficile ...
Cached Biology Technology:Novavax Announces Appointment of John J. Trizzino as Senior Vice President, International and Government Alliances 2EPA Refuge Determination Positive for the Environment 2BioNeutral's Ygiene(TM) Hospital Grade Achieves a 100% Total Kill (Pass) Against the Life Threatening Clostridium Difficile (C.diff) Spores in Independent EPA Required Protocol Testing. 2BioNeutral's Ygiene(TM) Hospital Grade Achieves a 100% Total Kill (Pass) Against the Life Threatening Clostridium Difficile (C.diff) Spores in Independent EPA Required Protocol Testing. 3
(Date:6/16/2015)... 16, 2015 Fingerprint Cards (FPC) raises ... it will amount to at least 340 MSEK to that ... rapid increase in market growth and orders received the revenue ... that revenue for 2015 will exceed 1,500 MSEK to an ... 2,200 MSEK. Due to receipt of orders of ...
(Date:6/12/2015)... -- Securus Technologies, a leading provider of civil and ... corrections and monitoring, announced the United States Patent ... and identify participants of a video visitation session ... system can: , Identify that the ... process is actually the person participating in the ...
(Date:6/9/2015)... -- Research and Markets  ( http://www.researchandmarkets.com/research/xsgs2s/gesture ) has ... & Touchless Sensing Market by Technology (Touch-based & ... (Biometric & Sanitary Equipment) & by Geography - ... offering. The total gesture recognition and ... 23.55 Billion by 2020 at a high CAGR ...
Breaking Biology News(10 mins):Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3Securus Announces Patent Issued for Authorized Presence Verification During Video Visitation 2Global Gesture Recognition & Touchless Sensing (Technology, Application & Products) Market 2015-2020 2
... class of ring-shaped protein motors has been uncovered by ... using a state-of-the-art protein crystallography beamline at the Advanced ... in gene expression and replication, and are vital to ... infectious agents, such as the human papillomavirus, which has ...
... debate. A high-profile study a few years ago suggested that ... and leaves, evidence for a very close link between the ... University of Washington shows this is not likely to be ... other aquatic life, according to research published this week in ...
... community-associated strain of the deadly superbug MRSAan infection-causing bacteria resistant ... previously known and is making its way into hospitals, according ... Infectious Diseases . The new threat is easily ... and has increased the overall burden of MRSA within hospitals, ...
Cached Biology News:Atomic-level snapshot catches protein motor in action 2Atomic-level snapshot catches protein motor in action 3Atomic-level snapshot catches protein motor in action 4Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3New study finds MRSA on the rise in hospital outpatients 2
... is the cycler that revolutionized thermal ... and swappable blocks ensure consistent results, ... rugged machine is more than just ... new features and upgrades as research ...
... Array (MSTA) slides were designed to study protein ... multiple species. Tissue slices from three different ... can then be treated as a single histological ... situ hybridization. This format allows a ...
... solution. In PBS containing ... other proprietary stabilizers; 0.2 ... to stabilize activity of ... at high conjugate dilutions ...
... used to predict the melting ... up to 3,200 bases, which ... primers and GC clamps for ... gel electrophoresis (DGGE), constant denaturing ...
Biology Products: